Merck

The RSI indicator, used to identify 'overheated' stocks, signaled this week a series of stocks that surged rapidly—led by Moderna and Merck following a breakthrough in cancer vaccine development. What does this indicator mean, and why is it not necessarily a sell signal?

While Moderna grabbed headlines with a 177% jump, its partner Merck recorded its best day since 2009. Morgan Stanley has upgraded its recommendation, highlighting the company's potential beyond its flagship drug, despite the looming patent expiration.

An experimental personalized cancer vaccine for melanoma from Merck and Moderna has shown positive preliminary results in its first late-stage trial. The combination therapy significantly extended the time patients lived without recurrence.

An experimental personalized cancer vaccine from Merck and Moderna has shown positive preliminary results in a Phase 3 trial. The combination therapy significantly reduced the risk of melanoma recurrence.